Skip to main navigation
  • About
    • Overview
    • Mission & Vision
    • Operating Principles
    • Management
    • Board of Directors
  • Science
    • Overview
    • Therapeutic Areas
    • Therapeutic Platforms
    • Technology Platforms
    • Publications
  • Pipeline
    • Overview
    • Precigen Pipeline
    • Expanded Access Policy
  • Subsidiaries
    • Overview
    • Precigen Actobio
    • Precigen Exemplar
  • Careers
    • Overview
    • Job Postings
    • Postdoc Program
    • Benefits
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock
    • Financials
    • Governance
    • Resources
  • Contact
    • Contact
    • Locations
  • About
    • Overview
    • Mission & Vision
    • Operating Principles
    • Management
    • Board of Directors
  • Science
    • Overview
    • Therapeutic Areas
    • Therapeutic Platforms
    • Technology Platforms
    • Publications
  • Pipeline
    • Overview
    • Precigen Pipeline
    • Expanded Access Policy
  • Subsidiaries
    • Overview
    • Precigen Actobio
    • Precigen Exemplar
  • Careers
    • Overview
    • Job Postings
    • Postdoc Program
    • Benefits
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock
    • Financials
    • Governance
    • Resources
  • Contact
    • Contact
    • Locations
PRECIGEN Investors

Events

IR Nav

  • Press Releases
  • Events & Presentations
  • Stock
  • Financials
  • Governance
  • Resources

Precigen Business and Clinical Update

Apr 04, 2023 at 8:30 AM EDT

Precigen will host a conference call to provide business and clinical updates for recent announcements.

Webcast

Supporting Materials

Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T®
Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors
Advancing Medicine with precision™
  • About
    • Overview
    • Mission & Vision
    • Operating Principles
    • Management
    • Board of Directors
  • Science
    • Overview
    • Therapeutic Areas
    • Therapeutic Platforms
    • Technology Platforms
    • Publications
  • Pipeline
    • Overview
    • Precigen Pipeline
    • Expanded Access Policy
  • Subsidiaries
    • Overview
    • Precigen Actobio
    • Precigen Exemplar
  • Careers
    • Overview
    • Job Postings
    • Postdoc Program
    • Benefits
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock
    • Financials
    • Governance
    • Resources
  • Contact
    • Contact
    • Locations

Headquarters

Precigen, Inc.
20358 Seneca Meadows Parkway
Germantown, MD 20876

Connect

  • linkedin
  • twitter
  • youtube

Privacy and Legal Menu

  • Privacy Policy
  • Legal Notices

Copyright

© Precigen. All Rights Reserved.